Targeting MET in cancer: Rationale and progress

Nature Reviews Cancer

Volumn 12, Issue 2, 2012, Pages 89-103

  Gherardi, Ermanno ^a,b   Birchmeier, Walter ^c   Birchmeier, Carmen ^c   Woude, George Vande ^d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 777607; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FOCAL ADHESION KINASE; LAPATINIB; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PLACEBO; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; WNT PROTEIN; WNT7B PROTEIN;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; EMBRYO DEVELOPMENT; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; UBIQUITINATION;

EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84856152266     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3205     Document Type: Review

References (187)

1. Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33 (1984). (Pubitemid 14065275)
2. Park, M. et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl Acad. Sci. USA 84, 6379-6383 (1987). (Pubitemid 18002806)
3. Rong, S., Segal, S., Anver, M., Resau, J. H. & Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl Acad. Sci. USA 91, 4731-4735 (1994). (Pubitemid 24177723)
4. Miyazawa, K. et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967-973 (1989). (Pubitemid 19236944)
5. Nakamura, T., Nawa, K., Ichihara, A., Kaise, N. & Nishino, T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 224, 311-316 (1987).
6. Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443 (1989). (Pubitemid 19277521)
7. Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314-3320 (1989). (Pubitemid 19162144)
8. Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242 (1987). (Pubitemid 17071053)
9. Gherardi, E., Gray, J., Stoker, M., Perryman, M. & Furlong, R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc. Natl Acad. Sci. USA 86, 5844-5848 (1989). (Pubitemid 19217546)
10. Gherardi, E. & Stoker, M. Hepatocytes and scatter factor. Nature 346, 228 (1990). (Pubitemid 20227395)
11. Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001-7005 (1991). (Pubitemid 21915077)
12. Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991). (Pubitemid 21926175)
13. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702 (1995).
14. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705 (1995).
15. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995).
16. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4, 915-925 (2003).
17. Weidner, K. M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173-176 (1996). (Pubitemid 26386473)
18. Lai, A. Z., Abella, J. V. & Park, M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-551 (2009).
19. Trusolino, L., Bertotti, A. & Comoglio, P. M. MET signalling: principles and functions in development, organ regeneration and cancer. Nature Rev. Mol. Cell Biol. 11, 834-848 (2010).
20. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68-73 (1997). (Pubitemid 27198158)
21. Schiering, N. et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl Acad. Sci. USA 100, 12654-12659 (2003). (Pubitemid 37339954)
22. Gherardi, E. et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl Acad. Sci. USA 103, 4046-4051 (2006).
23. Kirchhofer, D. et al. Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J. Biol. Chem. 279, 39915-39924 (2004). (Pubitemid 39258264)
24. Owen, K. A. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 426, 219-228 (2010).
25. Shimomura, T. et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J. Biol. Chem. 268, 22927-22932 (1993). (Pubitemid 23318359)
26. Shimomura, T. et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 6370-6376 (1997). (Pubitemid 27118113)
27. Kawaguchi, T. et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 27558-27564 (1997). (Pubitemid 27473546)
28. List, K. et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 19, 1934-1950 (2005). (Pubitemid 41186993)
29. Klezovitch, O. et al. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185-195 (2004). (Pubitemid 39485690)
30. Morris, M. R. et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 65, 4598-4606 (2005). (Pubitemid 40740795)
31. Chirgadze, D. Y. et al. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nature Struct. Biol. 6, 72-79 (1999). (Pubitemid 29232427)
32. Ultsch, M., Lokker, N. A., Godowski, P. J. & de Vos, A. M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure 6, 1383-1393 (1998). (Pubitemid 28541882)
33. Tolbert, W. D., Daugherty-Holtrop, J., Gherardi, E., Vande Woude, G. & Xu, H. E. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc. Natl Acad. Sci. USA 107, 13264-13269 (2010).
34. Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D. & Wiesmann, C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J. 23, 2325-2335 (2004). (Pubitemid 38954840)
35. Niemann, H. H. et al. Structure of the human receptor tyrosine kinase met in complex with the listeria invasion protein InlB. Cell 130, 235-246 (2007). (Pubitemid 47081132)
36. Ferraris, D. M., Gherardi, E., Di, Y., Heinz, D. W. & Niemann, H. H. Ligand-mediated dimerization of the Met receptor tyrosine kinase by the bacterial invasion protein InlB. J. Mol. Biol. 395, 522-532 (2010).
37. Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (1994). (Pubitemid 24138623)
38. Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513-8525 (2000).
39. Paliouras, G. N., Naujokas, M. A. & Park, M. Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol. Cell. Biol. 29, 3018-3032 (2009).
40. Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419-1432 (2000). (Pubitemid 30437616)
41. Schaeper, U. et al. Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo. Proc. Natl Acad. Sci. USA 104, 15376-15381 (2007). (Pubitemid 47502925)
42. Grossmann, K. S., Rosario, M., Birchmeier, C. & Birchmeier, W. The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res. 106, 53-89 (2010).
43. Ishibe, S. et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 136, 337-345 (2009).
44. Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901-908 (1991). (Pubitemid 121001504)
45. Woolf, A. S. et al. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J. Cell Biol. 128, 171-184 (1995).
46. Mosesson, Y., Mills, G. B. & Yarden, Y. Derailed endocytosis: an emerging feature of cancer. Nature Rev. Cancer 8, 835-850 (2008).
47. Joffre, C. et al. A direct role for Met endocytosis in tumorigenesis. Nature Cell Biol. 13, 827-837 (2011).
48. Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (2001). (Pubitemid 34031802)
49. Hammond, D. E., Urbe, S., Vande Woude, G. F. & Clague, M. J. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761-2770 (2001). (Pubitemid 32549833)
50. Petrelli, A. et al. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416, 187-190 (2002). (Pubitemid 34246477)
51. Abella, J. V. et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 25, 9632-9645 (2005). (Pubitemid 41507861)
52. Lee, J. H. et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19, 4947-4953 (2000).
53. Asaoka, Y. et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem. Biophys. Res. Commun. 394, 1042-1046 (2010).
54. Foveau, B. et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 20, 2495-2507 (2009).
55. Dietrich, S. et al. The role of SF/HGF and c-Met in the development of skeletal muscle. Development 126, 1621-1629 (1999). (Pubitemid 29204327)
56. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986). (Pubitemid 17052899)
57. Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60-66 (1997).
58. Borowiak, M. et al. Met provides essential signals for liver regeneration. Proc. Natl Acad. Sci. USA 101, 10608-10613 (2004). (Pubitemid 38955789)
59. Huh, C. G. et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101, 4477-4482 (2004).
60. Huelsken, J., Vogel, R., Erdmann, B., Cotsarelis, G. & Birchmeier, W. β-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105, 533-545 (2001). (Pubitemid 32520858)
61. Snippert, H. J. et al. Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. Science 327, 1385-1389 (2010).
62. Chmielowiec, J. et al. c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151-162 (2007). (Pubitemid 46588409)
63. Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y. & Matsuda, H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519 (2000). (Pubitemid 32038589)
64. Ma, P. C. et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47, 1025-1037 (2008).
65. Graveel, C. et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc. Natl Acad. Sci. USA 101, 17198-17203 (2004). (Pubitemid 39627797)
66. Ponzo, M. G. et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl Acad. Sci. USA 106, 12903-12908 (2009).
67. Di Renzo, M. F. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547-1555 (2000). (Pubitemid 30175676)
68. Houldsworth, J., Cordon-Cardo, C., Ladanyi, M., Kelsen, D. P. & Chaganti, R. S. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 50, 6417-6422 (1990). (Pubitemid 20323708)
69. Kuniyasu, H. et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189, 227-232 (1992). (Pubitemid 23030031)
70. Rege-Cambrin, G. et al. Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet. Cytogenet. 64, 170-173 (1992). (Pubitemid 23044958)
71. Knudsen, B. S. & Vande Woude, G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87-96 (2008). (Pubitemid 351694452)
72. Bauer, T. W. et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer Ther. 5, 1676-1682 (2006). (Pubitemid 44323235)
73. Khoury, H. et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 16, 550-561 (2005). (Pubitemid 40165554)
74. Yamamoto, N., Mammadova, G., Song, R. X., Fukami, Y. & Sato, K. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J. Cell Sci. 119, 4623-4633 (2006). (Pubitemid 44964259)
75. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). (Pubitemid 46799492)
76. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
77. Zhang, Y. W. et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-6890 (2010).
78. Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720-724 (2002). (Pubitemid 34993710)
79. Swiercz, J. M., Worzfeld, T. & Offermanns, S. Semaphorin 4D signaling requires the recruitment of phospholipase C γ into the plexin-B1 receptor complex. Mol. Cell. Biol. 29, 6321-6334 (2009).
80. Klaus, A. & Birchmeier, W. Wnt signalling and its impact on development and cancer. Nature Rev. Cancer 8, 387-398 (2008). (Pubitemid 351589714)
81. Boon, E. M., van der Neut, R., van de Wetering, M., Clevers, H. & Pals, S. T. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62, 5126-5128 (2002). (Pubitemid 35024579)
82. Liu, Y. et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development 136, 843-853 (2009).
83. Monga, S. P. et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res. 62, 2064-2071 (2002). (Pubitemid 34408453)
84. Brembeck, F. H. et al. Essential role of BCL9-2 in the switch between β-catenin's adhesive and transcriptional functions. Genes Dev. 18, 2225-2230 (2004). (Pubitemid 39209569)
85. Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004). (Pubitemid 38174665)
86. Sridhar, S. C. & Miranti, C. K. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25, 2367-2378 (2006).
87. Takahashi, M., Sugiura, T., Abe, M., Ishii, K. & Shirasuna, K. Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int. J. Cancer 121, 1919-1929 (2007). (Pubitemid 47463154)
88. Sharp, R. et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nature Med. 8, 1276-1280 (2002). (Pubitemid 35373560)
89. Abounader, R. & Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7, 436-451 (2005). (Pubitemid 41555616)
90. Bussolino, F. et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641 (1992).
91. Grant, D. S. et al. Scatter factor induces blood vessel formation in vivo. Proc. Natl Acad. Sci. USA 90, 1937-1941 (1993). (Pubitemid 23069972)
92. Zhang, Y. W., Su, Y., Volpert, O. V. & Vande Woude, G. F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl Acad. Sci. USA 100, 12718-12723 (2003). (Pubitemid 37339965)
93. Sulpice, E. et al. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell 101, 525-539 (2009).
94. Puri, N. et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-3534 (2007). (Pubitemid 46762132)
95. Cantelmo, A. R. et al. Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene 29, 5286-5298 (2010).
96. Hara, S. et al. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1α in human salivary gland cancer cells. Oral Oncol. 42, 593-598 (2006). (Pubitemid 43947665)
97. Ide, T. et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int. J. Cancer 119, 2750-2759 (2006). (Pubitemid 44846225)
98. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003). (Pubitemid 38340304)
99. Scarpino, S. et al. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J. Pathol. 202, 352-358 (2004). (Pubitemid 38325245)
100. Qian, F. et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-8016 (2009).
101. Nakagawa, T. et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 101, 210-215 (2010).
102. You, W. K. & McDonald, D. M. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 41, 833-839 (2008).
103. Meiners, S., Brinkmann, V., Naundorf, H. & Birchmeier, W. Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 16, 9-20 (1998). (Pubitemid 28043504)
104. Gallego, M. I., Bierie, B. & Hennighausen, L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22, 8498-8508 (2003). (Pubitemid 37523901)
105. Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA 95, 14417-14422 (1998). (Pubitemid 28549382)
106. Moshitch-Moshkovitz, S. et al. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia 8, 353-363 (2006). (Pubitemid 43830742)
107. Giordano, S. et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl Acad. Sci. USA 94, 13868-13872 (1997). (Pubitemid 28009676)
108. Muschel, R. J., Williams, J. E., Lowy, D. R. & Liotta, L. A. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am. J. Pathol. 121, 1-8 (1985). (Pubitemid 16232385)
109. Webb, C. P. et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17, 2019-2025 (1998). (Pubitemid 28499328)
110. Ridley, A. J., Comoglio, P. M. & Hall, A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell. Biol. 15, 1110-1122 (1995).
111. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biol. 12, 468-476 (2010).
112. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997). (Pubitemid 27298715)
113. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007). (Pubitemid 47106366)
114. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006).
115. Malanchi, I. et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452, 650-653 (2008). (Pubitemid 351483363)
116. Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765 (2006). (Pubitemid 44949605)
117. Wend, P., Holland, J. D., Ziebold, U. & Birchmeier, W. Wnt signaling in stem and cancer stem cells. Semin. Cell Dev. Biol. 21, 855-863 (2010).
118. Neuss, S., Becher, E., Woltje, M., Tietze, L. & Jahnen-Dechent, W. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22, 405-414 (2004). (Pubitemid 38736624)
119. Son, B. R. et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24, 1254-1264 (2006).
120. Tesio, M. et al. Enhanced c-Met activity promotes G.-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood 117, 419-428.
121. Urbanek, K. et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res. 97, 663-673 (2005). (Pubitemid 41416335)
122. Tatsumi, R., Anderson, J. E., Nevoret, C. J., Halevy, O. & Allen, R. E. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev. Biol. 194, 114-128 (1998). (Pubitemid 28115263)
123. Kamiya, A., Gonzalez, F. J. & Nakauchi, H. Identification and differentiation of hepatic stem cells during liver development. Front. Biosci. 11, 1302-1310 (2006). (Pubitemid 43253423)
124. Suzuki, A., Nakauchi, H. & Taniguchi, H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 53, 2143-2152 (2004). (Pubitemid 38970768)
125. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
126. Previdi, S. et al. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways. Eur. J. Cancer 46, 1679-1691 (2010).
127. Masuya, D. et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br. J. Cancer 90, 1555-1562 (2004). (Pubitemid 38648238)
128. Mahtouk, K., Tjin, E. P., Spaargaren, M. & Pals, S. T. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim. Biophys. Acta 1806, 208-219 (2010).
129. Sukhdeo, K. et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl Acad. Sci. USA 104, 7516-7521 (2007). (Pubitemid 47185938)
130. Shia, S. et al. Conformational lability in serine protease active sites: structures of Hepatocyte Growth Factor Activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J. Mol. Biol. 346, 1335-1349 (2005). (Pubitemid 40248833)
131. Li, W. et al. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res. 69, 8395-8402 (2009).
132. Wu, Y. et al. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc. Natl Acad. Sci. USA 104, 19784-19789 (2007).
133. Ganesan, R. et al. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Structure 17, 1614-1624 (2009).
134. Farady, C. J., Sun, J., Darragh, M. R., Miller, S. M. & Craik, C. S. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J. Mol. Biol. 369, 1041-1051 (2007). (Pubitemid 46754067)
135. Cao, B. et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl Acad. Sci. USA 98, 7443-7448 (2001). (Pubitemid 32567968)
136. Burgess, T. L. et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol. Cancer Ther. 9, 400-409 (2010).
137. Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol. Cell. Biol. 18, 1275-1283 (1998). (Pubitemid 28100891)
138. Tolbert, W. D. et al. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc. Natl Acad. Sci. USA 104, 14592-14597 (2007). (Pubitemid 350003189)
139. Youles, M. et al. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J. Mol. Biol. 377, 616-622 (2008).
140. Otsuka, T. et al. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell. Biol. 20, 2055-2065 (2000). (Pubitemid 30123821)
141. Date, K., Matsumoto, K., Shimura, H., Tanaka, M. & Nakamura, T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 420, 1-6 (1997). (Pubitemid 28037188)
142. Nakamura, T., Sakai, K. & Matsumoto, K. Anti-cancer approach with NK4: bivalent action and mechanisms. Anticancer Agents Med. Chem. 10, 36-46 (2010).
143. Kong-Beltran, M., Stamos, J. & Wickramasinghe, D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6, 75-84 (2004). (Pubitemid 38903163)
144. Jin, H. et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008).
145. Petrelli, A. et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl Acad. Sci. USA 103, 5090-5095 (2006).
146. Schelter, F. et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem. 285, 26335-26340 (2010).
147. Pacchiana, G. et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J. Biol. Chem. 285, 36149-36157 (2010).
148. Goetsch, L. Novel antibodies inhibitong c-met dimerization, and uses thereof (2007). http://ip.com/patapp/EP2188312A2.
149. Underiner, T. L., Herbertz, T. & Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med. Chem. 10, 2188317-2188327 (2010).
150. Wang, W. et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl Acad. Sci. USA 103, 3563-3568 (2006). (Pubitemid 43376595)
151. Rickert, K. W. et al. Structural basis for selective small-molecule kinase inhibition of activated c-Met. J. Biol. Chem. 286, 11218-11225 (2011).
152. Buchanan, S. G. et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 8, 3181-3190 (2009).
153. Timofeevski, S. L. et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48, 5339-5349 (2009).
154. Schroeder, G. M. et al. Discovery of N-(4-(2-amino-3-chloropyridin-4- yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluor ophenyl)-2-oxo-1,2-dihydropyridi ne-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J. Med. Chem. 52, 1251-1254 (2009).
155. D'Angelo, N. D. et al. Design, synthesis, and biological evaluation of potent c-Met inhibitors. J. Med. Chem. 51, 5766-5779 (2008).
156. Munshi, N. et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544-1553 (2010).
157. Eathiraj, S. et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J. Biol. Chem. 286, 20666-20676 (2011).
158. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
159. O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003). (Pubitemid 36302244)
160. Knudsen, B. S. et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl. Immunohistochem. Mol. Morphol. 17, 57-67 (2009).
161. Inoue, T. et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95, 803-808 (2004). (Pubitemid 39545586)
162. Mueller, K. L., Hunter, L. A., Ethier, S. P. & Boerner, J. L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 68, 3314-3322 (2008).
163. Zhang, Y., Guessous, F., Kofman, A., Schiff, D. & Abounader, R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 13, 112-121 (2010).
164. Cepero, V. et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70, 7580-7590 (2010).
165. Corso, S. et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol. Cancer 9, 121 (2010).
166. Qi, J. et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 71, 1081-1091 (2011).
167. Spigel DR. et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. Abstr. 29, 7505 (2011).
168. Iveson, T. et al. Safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma. Proc. Eur. Multidisc. Cancer Congr. Abstr. 6.504 (Stockholm, 2011).
169. Von Pawel J. et al. Final results from Arq 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor Nave patients with advanced non-small cell lung cancer (NSCLC). J. Thoracic Oncol. Abstr. 5, 1 (2010).
170. Bagai, R., Fan, W. & Ma, P. C. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs 13, 404-414 (2010).
171. Gordon MS. et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J. Clin. Oncol. Abstr. 29, 3010 (2011).
172. Buckanovich RJ. et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J. Clin. Oncol. Abstr. 29, 5008 (2011).
173. Hussain M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J. Clin. Oncol. 29, 4516 (2011).
174. Kurzrock, R. et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011).
175. Liu, L. et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1-or HER2-coactivated tumor cells. Mol. Cancer Ther. 10, 518-530 (2011).
176. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
177. Komada, M. et al. Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin. FEBS Lett. 328, 25-29 (1993). (Pubitemid 23234758)
178. Gherardi, E. et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc. Natl Acad. Sci. USA 100, 12039-12044 (2003). (Pubitemid 37271511)
179. Holmes, O. et al. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J. Mol. Biol. 367, 395-408 (2007). (Pubitemid 46295423)
180. DeLano, W. L. The PyMOL Molecular Graphics System. (DeLano Scientific, 2002).
181. Weidner, K. M., Behrens, J., Vandekerckhove, J. & Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097-2108 (1990).
182. Rong, S. et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. 12, 5152-5158 (1992).
183. Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 7, 1513-1523 (1996). (Pubitemid 26378346)
184. Itoh, M. et al. Role of Gab1 in heart, placenta, and skin development and growth factor-and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20, 3695-3704 (2000). (Pubitemid 30243915)
185. Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384 (2000).
186. Shen, Y., Naujokas, M., Park, M. & Ireton, K. InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell 103, 501-510 (2000).
187. Stein, U. et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature Med. 15, 59-67 (2009).